Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06612268 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
A Phase 3 study of Sickle Cell Disease, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
- 20
- Study locations
NCT06612268: Recruiting Phase 3 study of Sickle Cell Disease, sponsored by Novo Nordisk A/S.
NCT06612268 is a Phase 3 study of Sickle Cell Disease that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 408 participants, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06612268, a Phase 3 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
Primary Outcome
Measured as Count of events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Etavopivat
Study Locations (20)
California
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
- UCLA Health - Los Angeles
- Valley Children's Hospital - Madera
- University Of California Irvine - Orange
- Stanford University_Palo Alto - Palo Alto
- Harbor-UCLA Medical Center - Torrance
Alabama
- Uni of Alabama at Birmingham - Birmingham
- Univer South Alabama Ped/Onc - Mobile
District of Columbia
- Childrens National Medical Ctr - Washington D.C.
- MedStar Hlth Res Institute - Washington D.C.
Illinois
- Childrens Hospital of Chicago - Chicago
- Univer Of Illinois at Chicago - Chicago
Arizona
- Phoenix Children's Hsptl - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Clinical and Transl Res Center - Aurora
Delaware
- Nemours/AI duPont Hosp-Chld - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2029-03-12 |
| Phase | Phase 3 |
What NCT06612268 shows while recruiting
NCT06612268 is an interventional study that assigns participants to a tested intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (40% higher).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06612268 names 20 study sites across 12 states, led by California, Alabama, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06612268 about?
NCT06612268 is a clinical study titled "A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease". This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can redu...
What is the current status of trial NCT06612268?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2025-02-17. Estimated completion is 2029-03-12.
What conditions does trial NCT06612268 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT06612268?
The interventions under investigation include: Placebo (DRUG), Etavopivat (DRUG).
Who is sponsoring clinical trial NCT06612268?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06612268 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06612268's enrollment target sits among peer trials
408 12th of 213 higher than 202 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06662500 · 408 participants · NA
FORWARD CAD IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI